Literature DB >> 25331116

EVI1-rearranged acute myeloid leukemias are characterized by distinct molecular alterations.

Vincent-Philippe Lavallée1, Patrick Gendron2, Sébastien Lemieux3, Giovanni D'Angelo4, Josée Hébert5, Guy Sauvageau5.   

Abstract

The genetic and transcriptional signature of EVI1 (ecotropic viral integration site 1)-rearranged (EVI1-r) acute myeloid leukemias (AMLs) remains poorly defined. We performed RNA sequencing of 12 EVI1-r AMLs and compared the results with those of other AML subtypes (n = 139) and normal CD34(+) cells (n = 17). Results confirm high frequencies of RAS and other activated signaling mutations (10/12 AMLs) and identify new recurrent mutations in splicing factors (5/12 AMLs in SF3B1 and 2/12 AMLs in U2AF1), IKZF1 (3/12 AMLs), and TP53 (3/12 AMLs). Mutations in IKZF1, a gene located on chromosome 7, and monosomy 7 are mutually exclusive in this disease. Moreover IKZF1 expression is halved in monosomy 7 leukemias. EVI-r AMLs are also characterized by a unique transcriptional signature with high expression levels of MECOM, PREX2, VIP, MYCT1, and PAWR. Our results suggest that EVI1-r AMLs could be molecularly defined by specific transcriptomic anomalies and a hitherto unseen mutational pattern. Larger patient cohorts will better determine the frequency of these events.
© 2015 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25331116      PMCID: PMC4358966          DOI: 10.1182/blood-2014-07-591529

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  23 in total

1.  Targeting of Ikaros to pericentromeric heterochromatin by direct DNA binding.

Authors:  B S Cobb; S Morales-Alcelay; G Kleiger; K E Brown; A G Fisher; S T Smale
Journal:  Genes Dev       Date:  2000-09-01       Impact factor: 11.361

2.  Myc target in myeloid cells-1, a novel c-Myc target, recapitulates multiple c-Myc phenotypes.

Authors:  Xiaoying Yin; Linnette Grove; Kenneth Rogulski; Edward V Prochownik
Journal:  J Biol Chem       Date:  2002-03-21       Impact factor: 5.157

3.  High frequencies of SF3B1 and JAK2 mutations in refractory anemia with ring sideroblasts associated with marked thrombocytosis strengthen the assignment to the category of myelodysplastic/myeloproliferative neoplasms.

Authors:  Sabine Jeromin; Torsten Haferlach; Vera Grossmann; Tamara Alpermann; Andreas Kowarsch; Claudia Haferlach; Wolfgang Kern; Susanne Schnittger
Journal:  Haematologica       Date:  2012-08-28       Impact factor: 9.941

4.  Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study.

Authors:  Heesun J Rogers; James W Vardiman; John Anastasi; Gordana Raca; Natasha M Savage; Athena M Cherry; Daniel Arber; Erika Moore; Jennifer J D Morrissette; Adam Bagg; Yen-Chun Liu; Susan Mathew; Attilio Orazi; Pei Lin; Sa A Wang; Carlos E Bueso-Ramos; Kathryn Foucar; Robert P Hasserjian; Ramon V Tiu; Matthew Karafa; Eric D Hsi
Journal:  Haematologica       Date:  2014-01-24       Impact factor: 9.941

5.  Activation of Evi1 inhibits cell cycle progression and differentiation of hematopoietic progenitor cells.

Authors:  O S Kustikova; A Schwarzer; M Stahlhut; M H Brugman; T Neumann; M Yang; Z Li; A Schambach; N Heinz; S Gerdes; I Roeder; T C Ha; D Steinemann; B Schlegelberger; C Baum
Journal:  Leukemia       Date:  2012-12-05       Impact factor: 11.528

Review 6.  The phosphoinositide 3-kinase/Akt1/Par-4 axis: a cancer-selective therapeutic target.

Authors:  Anindya Goswami; Padhma Ranganathan; Vivek M Rangnekar
Journal:  Cancer Res       Date:  2006-03-15       Impact factor: 12.701

7.  Preferential expression of the vasoactive intestinal peptide (VIP) receptor VPAC1 in human cord blood-derived CD34+CD38- cells: possible role of VIP as a growth-promoting factor for hematopoietic stem/progenitor cells.

Authors:  M Kawakami; T Kimura; Y Kishimoto; T Tatekawa; Y Baba; T Nishizaki; N Matsuzaki; Y Taniguchi; S Yoshihara; K Ikegame; T Shirakata; S Nishida; T Masuda; N Hosen; A Tsuboi; Y Oji; Y Oka; H Ogawa; Y Sonoda; H Sugiyama; I Kawase; T Soma
Journal:  Leukemia       Date:  2004-05       Impact factor: 11.528

8.  Molecular pathways: P-Rex in cancer.

Authors:  Atanasio Pandiella; Juan Carlos Montero
Journal:  Clin Cancer Res       Date:  2013-06-10       Impact factor: 12.531

9.  High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients.

Authors:  Sahar Barjesteh van Waalwijk van Doorn-Khosrovani; Claudia Erpelinck; Wim L J van Putten; Peter J M Valk; Sonja van der Poel-van de Luytgaarde; Ronald Hack; Rosalyn Slater; Elisabeth M E Smit; H Berna Beverloo; Gregor Verhoef; Leo F Verdonck; Gert J Ossenkoppele; Pieter Sonneveld; Georgine E de Greef; Bob Löwenberg; Ruud Delwel
Journal:  Blood       Date:  2002-10-03       Impact factor: 22.113

10.  A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia.

Authors:  Stefan Gröschel; Mathijs A Sanders; Remco Hoogenboezem; Elzo de Wit; Britta A M Bouwman; Claudia Erpelinck; Vincent H J van der Velden; Marije Havermans; Roberto Avellino; Kirsten van Lom; Elwin J Rombouts; Mark van Duin; Konstanze Döhner; H Berna Beverloo; James E Bradner; Hartmut Döhner; Bob Löwenberg; Peter J M Valk; Eric M J Bindels; Wouter de Laat; Ruud Delwel
Journal:  Cell       Date:  2014-04-03       Impact factor: 41.582

View more
  22 in total

1.  Identification of MYC mutations in acute myeloid leukemias with NUP98-NSD1 translocations.

Authors:  V-P Lavallée; S Lemieux; G Boucher; P Gendron; I Boivin; S Girard; J Hébert; G Sauvageau
Journal:  Leukemia       Date:  2016-02-09       Impact factor: 11.528

2.  The closely related rare and severe acute myeloid leukemias carrying EVI1 or PRDM16 rearrangements share singular biological features.

Authors:  Marion Eveillard; Jacques Delaunay; Steven Richebourg; Laurence Lodé; Richard Garand; Soraya Wuillème; François Duhoux; Hélène Antoine-Poirel; Catherine Godon; Marie C Béné
Journal:  Haematologica       Date:  2015-03       Impact factor: 9.941

Review 3.  Genetics of MDS.

Authors:  Seishi Ogawa
Journal:  Blood       Date:  2019-01-22       Impact factor: 22.113

4.  Therapy-related myelodysplastic syndrome: a case study.

Authors:  Masahiro Manabe; Katsuya Wada; Dai Momose; Yasuyoshi Sugano; Masayuki Hino; Takahisa Yamane; Eiwa Ishida; Ki-Ryang Koh
Journal:  Am J Blood Res       Date:  2015-12-25

5.  3q26.2/EVI1 rearrangement is associated with poor prognosis in classical Philadelphia chromosome-negative myeloproliferative neoplasms.

Authors:  Zhihong Hu; L Jeffrey Medeiros; Wei Wang; Zi Chen; Guilin Tang; Parsa Hodjat; Su Yang; Lianghua Fang; Yan Li; Srdan Verstovsek; Shimin Hu
Journal:  Mod Pathol       Date:  2017-03-24       Impact factor: 7.842

6.  Mutational Landscape and Gene Expression Patterns in Adult Acute Myeloid Leukemias with Monosomy 7 as a Sole Abnormality.

Authors:  Ann-Kathrin Eisfeld; Jessica Kohlschmidt; Krzysztof Mrózek; Stefano Volinia; James S Blachly; Deedra Nicolet; Christopher Oakes; Karl Kroll; Shelley Orwick; Andrew J Carroll; Richard M Stone; John C Byrd; Albert de la Chapelle; Clara D Bloomfield
Journal:  Cancer Res       Date:  2016-10-26       Impact factor: 12.701

7.  The transcriptomic landscape and directed chemical interrogation of MLL-rearranged acute myeloid leukemias.

Authors:  Vincent-Philippe Lavallée; Irène Baccelli; Jana Krosl; Brian Wilhelm; Frédéric Barabé; Patrick Gendron; Geneviève Boucher; Sébastien Lemieux; Anne Marinier; Sylvain Meloche; Josée Hébert; Guy Sauvageau
Journal:  Nat Genet       Date:  2015-08-03       Impact factor: 38.330

8.  A Dysregulated DNA Methylation Landscape Linked to Gene Expression in MLL-Rearranged AML.

Authors:  Michael A Koldobskiy; Jordi Abante; Garrett Jenkinson; Elisabet Pujadas; Ashley Tetens; Feifei Zhao; Rakel Tryggvadottir; Adrian Idrizi; Andreas Reinisch; Ravindra Majeti; John Goutsias; Andrew P Feinberg
Journal:  Epigenetics       Date:  2020-02-29       Impact factor: 4.528

9.  Myeloid neoplasms associated with t(3;12)(q26.2;p13) are clinically aggressive, show myelodysplasia, and frequently harbor chromosome 7 abnormalities.

Authors:  Arash Ronaghy; Shimin Hu; Zhenya Tang; Wei Wang; Guilin Tang; Sanam Loghavi; Shaoying Li; Beenu Thakral; L Jeffrey Medeiros; Tariq Muzzafar
Journal:  Mod Pathol       Date:  2020-10-27       Impact factor: 7.842

10.  Targeting an RNA-Binding Protein Network in Acute Myeloid Leukemia.

Authors:  Eric Wang; Sydney X Lu; Alessandro Pastore; Xufeng Chen; Jochen Imig; Stanley Chun-Wei Lee; Kathryn Hockemeyer; Yohana E Ghebrechristos; Akihide Yoshimi; Daichi Inoue; Michelle Ki; Hana Cho; Lillian Bitner; Andreas Kloetgen; Kuan-Ting Lin; Taisuke Uehara; Takashi Owa; Raoul Tibes; Adrian R Krainer; Omar Abdel-Wahab; Iannis Aifantis
Journal:  Cancer Cell       Date:  2019-02-21       Impact factor: 31.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.